Pancreatic ductal adenocarcinoma (PDA) is a lethal disease with limited response to
cytotoxic chemoradiotherapy, as well as newer immunotherapies. The PDA tumor …

Chemotherapy and immunotherapy for pancreatic ductal adenocarcinoma (PDAC) have
limited success. One reason for this is thought to be the cancer microenvironment …

Pancreatic cancer is one of the common malignant tumors of the digestive system and is
known as the “king of cancers”. It is extremely difficult to diagnose at an early stage, the …

With the advent of cancer immunotherapies, significant advances have been made in the
treatment of many tumor types including melanoma, lung cancer, squamous cell carcinoma …

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid tumors with
an overall five-year survival rate of that has only just reached 10%. The tumor …

Pancreatic ductal adenocarcinoma (PDAC) is composed of a minority of malignant cells
within a microenvironment of extracellular matrix, fibroblasts, endothelial cells, and immune …

Intratumoral hypoxia is a widely established element of the pancreatic tumor
microenvironment (TME) promoting immune escape, tumor invasion, and progression, while …

One of the key factors that correlates with poor survival of patients with pancreatic cancer is
the extent of hypoxic areas within the tumor tissue. The adaptation of pancreatic cancer cells …

Attributable to its late diagnosis, early metastasis, and poor prognosis, pancreatic cancer
remains one of the most lethal diseases worldwide. Unlike other solid tumors, pancreatic …

Background & Aims Pancreatic ductal adenocarcinoma (PDAC) has a hypoxic,
immunosuppressive stroma that contributes to its resistance to immune checkpoint blockade …